The Journal is included in Russian and International Library and Abstract Databases
Russain Science Index (Russia)
EBSCO
DOI Registration Agency (USA)

Neurometabolic drugs in the combination therapy of chronic cerebrovascular diseases

DOI: https://doi.org/10.29296/25877305-2018-11-12
Download full text PDF
Issue: 
11
Year: 
2018

A. Tyazhelnikov(1), Candidate of Medical Sciences; Z. Osmaeva(2); Professor P. Kamchatnov(3), MD; A. Chugunov(3), Candidate of Medical Sciences 1-City Consultative and Diagnostic Polyclinic One Hundred and Twenty-One, Moscow Healthcare Department 2-Chechen State University, Groznyi 3-N.I. Pirogov Russian National Research Medical University, Moscow

To prevent cerebrovascular diseases is the most effective way of solving the problem of brain vascular lesions. Incorporation of neurometabolic drugs in their combination therapy can improve the outcome of the already developed disease. The clinical effects of L-carnitine (Elkar) are considered in patients with acute and chronic cerebral ischemia. Its maximum effect is noted when non-drug treatment and adequate drug therapy are used at the same time.

Keywords: 
neurology
chronic cerebral ischemia
ischemic stroke
L-carnitine
Elkar
neurometabolic therapy
treatment



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Blinder P., Tsai P., Kaufhold J. et al. The cortical angiome: an interconnected vascular network with noncolumnar patterns of blood flow // Nat. Neurosci. – 2013; 16: 889–97. http://doi.org/10.1038/nn.3426
  2. Gulevskaja T.S., Morgunov V.A. Patologicheskaja anatomija narushenij mozgovogo krovoobraschenija pri ateroskleroze i arterial'noj gipertenzii / M.: Meditsina, 2009.
  3. Nishimura N., Rosidi N., Iadecola C. et al. Limitations of collateral flow after occlusion of a single cortical penetrating arteriole // J. Cereb. Blood Flow Metab. – 2010; 30: 1914–27. http://doi.org/10.1038/jcbfm.2010.157
  4. Kampoli A., Tousoulis D., Briasoulis A. et al. Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus // Curr. Pharm. Des. – 2011; 17 (37): 4147–58.
  5. McLauchlan D., Malik G., Robertson N. Cerebral amyloid angiopathy: subtypes, treatment and role in cognitive impairment // J. Neurol. – 2017; 264: 2184–6. https://doi.org/10.1007/s00415-017-8608-7
  6. Cooper L., Woodard T., Sigurdsson S. et al. Cerebrovascular Damage Mediates Relations Between Aortic Stiffness and Memory // Hypertension. – 2016; 67: 176–82. https://doi.org/10.1161/HYPERTENSIONAHA.115.06398
  7. Pase M., Himali J., Mitchell G. et al. Association of aortic stiffness with cognition and brain aging in young and middle-aged adults: the Framingham third generation cohort study // Hypertension. – 2016; 67 (3): 513–9. https://doi.org/10.1161/HYPERTENSIONAHA.115.06610
  8. Prystowsky E., Padanilam B. Preserve the Brain: Primary Goal in the Therapy of Atrial Fibrillation // J. Am. Coll. Cardiol. – 2013; 62 (6): 540–2. DOI: 10.1016/j.jacc.2013.04.038
  9. Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial // BMJ. – 2018; 361: k1675. https://doi.org/10.1136/bmj.k1675
  10. Gusev E., Skvortsova V. Brain Ischemia / New York, Boston, Dordecht, London: Kluwer Academic/Plenum Publishers, 2003.
  11. Kuzin V.M. Karnitina hlorid (25 let v klinicheskoj praktike) // RMZh. – 2003; 11 (10): 5–9.
  12. Suslina Z.A., Fedorova T.N., Maksimova M.Ju. i dr. Antioksidantnaja aktivnost' mildronata i L-karnitina pri lechenii patsientov s tserebrovaskuljarnymi zabolevanijami // Eksperim. klin. farm. – 2003; 66 (3): 32–5.
  13. McMackin C., Widlansky M., Hamburg N. et al. Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease // J. Clin. Hypertens (Greenwich). – 2007; 9 (4): 249–55.
  14. Volek J., Judelson D., Silvestre R. et al. Effects of carnitine supplementation on flow-mediated dilation and vascular inflammatory responses to a high-fat meal in healthy young adults // Am. J. Cardiol. – 2008; 102 (10): 1413–7.
  15. Gusev E.I., Kuzin V.M., Kolesnikova T.N. i dr. Karnitin – veduschij faktor regeneratsii nervnoj tkani // Med. informatsionnyj vestn. – 1999 (fevral'): 11–23.
  16. Gusev E.I., Skvortsova V.I. Nejroprotektivnaja terapija ishemicheskogo insul'ta // Nervnye bolezni. – 2002; 1: 3–10.
  17. Popova T.E. Osobennosti razvitija i korrektsii gipoksii u bol'nyh s ishemicheskim insul'tom. Dis. ... kand. med. nauk. M., 2001.
  18. Bodyhov M.K., Stahovskaja L.V., Salimov K.A. i dr. Otsenka bezopasnosti i effektivnosti preparata «El'kar» (levokarnitin) u patsientov v ostrom periode ishemicheskogo insul'ta v karotidnoj sisteme // RMZh. Nevrologija. Psihiatrija. – 2011; 19 (9): 3–8.
  19. Ferrari R., Merli E., Cicchitelli G. et al. Therapeutic effects of L-carnitine and propionyl-L-car- nitine on cardiovascular diseases: a review // Ann. NY Acad. Sci. – 2004; 1033: 79–91.
  20. Golovkin V., Zuev A., Privalova M. i dr. Kognitivnye narushenija i kardiorespiratornaja disfunktsija pri distsirkuljatornoj entsefalopatii s kardiotserebral'nym sindromom // Vrach. – 2018; 29 (4): 51–3. DOI: 10.29296/25877305-2018-04-09
  21. Chichanovskaja L.V., Bahareva O.N., Sorokina K.B. Issledovanie bezopasnosti i effektivnosti L-karnitina u bol'nyh v rannem vosstanovitel'nom periode ishemicheskogo insul'ta // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2017; 12 (2): 65–9.
  22. Svoboda Z., Kvetina J., Herink J. et al. Galantamine antiacetylcholinesterase activity in rat brain influenced by L-carnitine // Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. – 2005; 149 (2): 335–7.
  23. Natecz K., Miecz D., Berezowski V. et al. Carnitine: transport and physiological functions in the brain // Mol. Aspects Med. – 2004; 25 (5–6): 551–67.